NanoViricides (NNVC) 10-Q 14 Nov 14 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Sep. 30, 2014	Nov. 14, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'NANOVIRICIDES, INC.	'
Entity Central Index Key	'0001379006	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Non-accelerated Filer	'
Trading Symbol	'NNVC	'
Entity Common Stock, Shares Outstanding	'	57,106,568
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2015	'

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2014	Jun. 30, 2014
CURRENT ASSETS:	'	'
Cash and cash equivalents	$41,120,652	$36,696,892
Prepaid expenses	59,099	108,089
Other current assets	0	150,000
Total Current Assets	41,604,153	37,664,202
PROPERTY AND EQUIPMENT	'	'
Property and equipment	7,299,254	6,736,742
Accumulated depreciation	-1,291,318	-1,239,986
Property and equipment, net	6,007,936	5,496,756
TRADEMARK	'	'
Trademark	458,954	458,954
Accumulated amortization	-52,889	-50,696
Trademark, net	406,065	408,258
SECURITY DEPOSIT	1,000,000	1,000,000
Total Assets	49,018,154	44,569,216
CURRENT LIABILITIES:	'	'
Accounts payable	155,978	376,446
Accounts payable - related parties	331,448	758,676
Accrued expenses	265,463	91,838
Total Current Liabilities	752,889	1,226,960
LONG TERM LIABILITIES:	'	'
Derivative Liability	3,785,385	5,699,703
Total Long Term Liabilities	11,437,925	14,737,271
Total Liabilities	12,190,814	15,964,231
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY:	'	'
Common stock, $0.001 par value; 85,714,285 shares authorized;56,535,135 and 54,620,993 shares issued and outstanding, respectively	56,535	54,621
Additional paid-in capital	89,412,744	80,953,428
Accumulated deficit	-52,645,328	-52,406,258
Total Stockholders' Equity	36,827,340	28,604,985
Total Liabilities and Stockholders' Equity	49,018,154	44,569,216
Series B Debentures [Member]	'	'
LONG TERM LIABILITIES:	'	'
Debentures payable	4,195,296	4,037,568
Series C Debentures [Member]	'	'
LONG TERM LIABILITIES:	'	'
Debentures payable	3,457,244	5,000,000
Related Party [Member]	'	'
CURRENT ASSETS:	'	'
Prepaid expenses	424,402	709,221
Series A Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	3,389	3,194
Series B Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	$0	$0

Balance_Sheets_Parenthetical

Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2014	Jun. 30, 2014
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	85,714,285	85,714,285
Common stock, shares issued	56,535,135	54,620,993
Common stock, shares, outstanding	56,535,135	54,620,993
Series A Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	3,387,795	3,193,079
Preferred stock, shares outstanding	3,387,795	3,193,079
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
OPERATING EXPENSES	'	'
Research and development	$811,107	$1,174,221
Refund credit research and development costs	0	0
General and administrative	876,026	714,561
Total operating expenses	1,687,133	1,888,782
LOSS FROM OPERATIONS	-1,687,133	-1,888,782
OTHER INCOME (EXPENSE):	'	'
Interest income, net	39,323	9,560
Interest expense	-245,000	-120,986
Discount on convertible debentures	-260,578	-135,481
Beneficial conversion feature of convertible debentures	0	0
Change in fair market value of derivatives	1,914,318	-4,137,091
Other income (expense), net	1,448,063	-4,383,998
LOSS BEFORE INCOME TAXES	-239,070	-6,272,780
INCOME TAX PROVISION	0	0
NET LOSS	($239,070)	($6,272,780)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED: (in dollars per share)	($0.00)	($0.04)
Weighted average common shares outstanding - basic and diluted (in shares)	55,576,200	47,672,029

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($239,070)	($6,272,780)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Preferred shares issued for license	'	0
Series A Preferred shares issued as compensation	72,980	0
Common shares and warrants issued for services	38,250	32,250
Common shares issued for interest	'	'
Warrants granted to scientific advisory board	22,292	106,050
Amortization of deferred compensation	'	0
Depreciation	51,332	52,719
Amortization	2,193	2,193
Change in fair value of derivative liability	-1,914,318	4,137,091
Amortization of deferred financing expenses	'	0
Discount convertible debentures	260,578	135,481
Beneficial conversion feature of convertible debentures	0	0
Changes in operating assets and liabilities:	'	'
Prepaid expenses	48,990	-206,765
Other current assets	150,000	0
Deferred expenses	'	0
Accounts payable - trade	-220,468	144,802
Accounts payable - related parties	-427,228	429,258
Accrued expenses	173,625	115,253
Accrued payroll to officers and related payroll tax expense	'	0
NET CASH USED IN OPERATING ACTIVITIES	-1,696,025	-1,324,448
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Security deposit	0	-1,000,000
Purchase of property and equipment	-562,512	-2,273,989
Purchase of trademark	0	'
NET CASH USED IN INVESTING ACTIVITIES	-562,512	-3,273,989
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of convertible debentures	'	'
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs	'	9,690,450
Proceeds from exercise of stock options	0	0
Proceeds from exercise of warrants	6,682,297	185,624
Collection of stock subscriptions received	'	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,682,297	9,876,074
NET CHANGE IN CASH	4,423,760	5,277,637
Cash at beginning of period	36,696,892	13,923,245
Cash at end of period	41,120,652	19,200,882
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:	'	'
Interest paid	0	0
Income tax paid	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'
Common stock issued for services rendered	38,250	32,250
Common stock for interest	'	'
Preferred stock issued as compensation	72,980	0
Series A Preferred stock issued as discount on Debentures	1,645,606	'
Stock options issued to the officers as compensation	'	0
Stock warrants granted to scientific advisory board	22,292	106,050
Stock warrants granted to brokers	'	113,696
Common stock issued for interest on debentures	'	0
Shares of common stock issued in connection with debenture offering	'	0
Common stock issued upon conversion of convertible debentures	'	0
Debt discount related to beneficial conversion feature of convertible debt	'	0
Stock Warrants issued in connection with Private Placement	'	0
Common stock issued for accounts payable	'	0
Common stock issued for equipment	'	0
Related Party [Member]	'	'
Changes in operating assets and liabilities:	'	'
Prepaid expenses	284,819	'
Series B Convertible Preferred Stock [Member]	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of Convertible Preferred stock, net	'	'
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'
Common stock issued upon conversion of Preferred Stock	'	'
Common stock issued for dividends on Preferred Stock	'	'
Series C Convertible Preferred Stock [Member]	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of Convertible Preferred stock, net	'	0
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'
Common stock issued upon conversion of Preferred Stock	'	0
Common stock issued for dividends on Preferred Stock	'	'

Organization_and_Nature_of_Bus

Organization and Nature of Business	3 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 - Organization and Nature of Business
	NanoViricides, Inc. was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc. which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On May 12, 2005, the corporations were merged and Edot-com.com, Inc., the Nevada corporation, became the surviving entity.
	On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.
	Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 newly issued shares of ECMM common stock resulting in an aggregate of 100,000,000 shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of 4,000 shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.
	As a result of the Exchange transaction, the former NVI stockholders held approximately 80% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.
	On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.
	NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour Pharma on  September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.
	On February 15, 2010 the Company executed an Additional License Agreement with TheraCour Pharma, Inc. (“TheraCour”).  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Preferred Series A do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the holder’s approval. The 2,000,000 shares were valued at the par value of $2,000 (adjusted for the reverse split).
	We focus our research and clinical programs on specific anti-viral therapeutics. The Company’s platform technology is based on novel biomimetic nanomedicine constructs, called nanoviricides®. A nanoviricide is designed to “fool” the virus into binding to the nanoviricide in the same fashion that it would bind to the host cell. Because the host cell receptor and how the virus binds to it does not change despite all the changes in the virus, the Company believes that our broad-spectrum nanoviricides should continue to work against the virus despite the viral mutations and other changes. We are seeking to add to our existing portfolio of products through our internal discovery and clinical development programs and through an in-licensing strategy.
	The Company has held a pre-IND Meeting with the US FDA for its clinical drug candidate NV-INF-1 in the FluCide™ program. The Company is developing this injectable drug (NV-INF-1) for hospitalized patients with severe influenza, including immuno-compromised patients. The Company believes that this drug may also be usable as a single-dose injection in a medical office for less severe cases of influenza. The Company has also developed an oral anti-influenza drug candidate, NV-INF-2, with a very high degree of effectiveness when taken by mouth. This may be the first ever nanomedicine that is orally active. Both of these anti-influenza therapeutic candidates are “broad-spectrum”, i.e. they are expected to be effective against most if not all types of influenzas including Bird Flu H5N1, Highly Pathogenic Influenzas (HPI/HPAI), Epidemic Influenzas such as the 2009 “swine flu” H1N1/A/2009, and Seasonal Influenzas including the recent H3N2 influenza. The Company has already demonstrated that they have significantly superior activity when compared to oseltamivir (Tamiflu®) against two unrelated influenza A subtypes, namely, H1N1 and H3N2 in a highly lethal animal model. Both of these drug candidates can be used as prophylactics to protect at-risk personnel such as health-care workers and immediate family members and caretakers of a patient.
	The Company’s broad-spectrum drug candidate for the treatment of dengue viral infections, DengueCide™, has received “orphan drug” status from both the US FDA and the European Medicines Agency (“EMA”). This orphan drug status carries with it several tax benefits and other financial equivalent incentives. Notably, in the US, orphan drug status will enable us to gain a “Priority Review Voucher” that can be applied to another drug development program or can be sold for a consideration to another pharmaceutical company, once the drug is approved. The Company has therefore prioritized its Dengue drug development program.
	The Company is also developing an anti-HIV drug. The drug candidates in this HIVCide(™) program were found to have effectiveness equal to that of a triple drug HAART cocktail therapy in the standard humanized SCID-hu Thy/Liv mouse model. Moreover, the nanoviricides were long acting. Viral load suppression continued to hold for more than four weeks after stopping HIVCide treatment. The Company believes that the strong effect and sustained effect indicate that an HIVCide can be developed as a single agent that would provide “Functional Cure” from HIV/AIDS. The Company believes that substantially all HIV virus can be cleared upon HIVCide treatment, except the integrated viral genome in latent cells. This would enable discontinuation of treatment until HIV reemerges from the latent reservoir, which may be several months without any drugs. Moreover, the Company believes that this therapy would also minimize the chances of HIV transmission. The Company is currently optimizing the anti-HIV drug candidates. These drug candidates are effective against both the R5 and X4 subtypes of HIV-1 in cell cultures. The Company believes that these drug candidates are “broad-spectrum”, i.e. they are expected to be effective against most strains and mutants of HIV, and therefore escape of mutants from our drugs is expected to be minimal.
	The Company is also developing a broad-spectrum skin cream for the treatment of oral and genital herpesvirus infections (i.e. both HSV-1 and HSV-2).
	In addition, the Company is also developing broad-spectrum eye drops that are expected to be effective against a majority of the viral infections of the external eye. Most of these viral infections are from adenoviruses or from herpesviruses. The Company has shown excellent efficacy of its drug candidates against EKC (adenoviral epidemic kerato-conjunctivitis) in an animal model. In addition, the anti-HSV drug candidates have shown excellent efficacy in cell culture studies. The Company is also developing a skin cream formulation for the treatment of herpes cold sores or genital warts. Further, the Company is also developing a broad-spectrum drug against Dengue viruses that is expected to be useful for the treatment of any of the four major serotypes of dengue viruses, including in severe cases of dengue (DSS) and dengue hemorrhagic fever (DHF). DSS and DHF are thought to be caused by prior antibodies against dengue that a patient’s body creates to fight a second unrelated dengue infection, and the second virus uses these antibodies effectively to hitch a ride into human cells, thereby causing a more severe infection than in naive patients. In addition to these six drugs in development, the Company also has research programs against Rabies virus, Ebola and Marburg viruses, and others. To date, the Company does not have any commercialized products.
	Thus, at present, the Company has six commercially important drug programs in its pipeline that have shown significant successes in cell culture as well as animal models. In addition, in August 2014, the Company announced that it has restarted our anti-Ebola drug development program, in response to the current Ebola epidemic. The Company’s platform technology enables rapid development of drug candidates against novel infections. The Company believes that it will continue to expand its pipeline as available funds and opportunities permit.
	The Company is also working on scaling up production processes, and enabling c-GMP-compliant manufacture of its drug candidates in order to provide clinical supplies for the future human clinical trials of our drug candidates. Construction of the modern, multi-product, state-of-the-art nanomedicines manufacturing facility built for this purpose was completed in July, 2014. Cleaning and Validation, as well as custom equipment fit-outs are in progress at present. The facility was built by Inno-Haven, LLC, a special-purpose company established for this purpose. Inno-Haven is controlled and managed by Dr. Anil Diwan, the Company’s co-founder, President, and Chairman. Inno-haven purchased the building in 1 Controls Drive, Shelton, CT, in August 2011, with personal funds, and loans from family friends, at a time when NanoViricides was unable to support this critical endeavor. With the Company’s improved finances, the Company now intends to purchase this facility from Inno-Haven.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2 - Summary of Significant Accounting Policies
	Basis of Presentation – Interim Financial Information
	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management,   considered necessary for a fair presentation of the results for the interim periods presented.  Interim results are not necessarily indicative of the results for the full year.  The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s form 10-K for the fiscal year ended June 30, 2014 filed with the SEC on September 30, 2014.
	For a summary of significant accounting policies (which have not changed from June 30, 2014), see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014.
	Net Income (Loss) per Common Share
	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the	For the Fiscal
		Three Months	Year
		Ended	Ended
		September 30, 2014	September 30, 2013
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.35 per share expiring ten (10) years from the date of issuance	535,715	535,715
	Sub-total: stock options	535,715	535,715
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007  to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	466,486
	Warrants issued from June 15, 2008 through May 15, 2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2015	211,429	211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015	65,714	65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016	68,571	68,571
	Warrants issued from August 16, 2012 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017	68,571	68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through September 30, 2014	2,810,071	2,910,071
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017	17,143	17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018	58,910	58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017	17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $5.25 per share expiring January 24, 2019	76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018	17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018	17148
	Warrants issued on August 15, 2014 to SAB for services with an exercise price of $5.02 per share expiring on August 15, 2018	17,148
	Sub-total: warrants	5,925,231	6,386,680
	Total potentially outstanding dilutive common shares	6,460,946	6,922,395
	In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
	At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,960,785 based upon the Selling price of the Company’s common stock on September 30, 2014 of $3.06. At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,142,858.
	The Company has also issued 3,387,795 of $0.001 par value Convertible Preferred A shares to investors and others. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At September 30, 2014, the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into, is 11,857,283.
	Recently Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
	The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
	The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	The company has limited operations and is considered to be in the development stage. The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage. The Company adopted this guidance from June 30, 2014
	In June 2014, the FASB issued the FASB Accounting Standards Update No. 2014-12 “Compensation—Stock Compensation (Topic 718) : Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).
	The amendments clarify the proper method of accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period.  The Update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition.  The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015.  Earlier adoption is permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements— Going Concern (Subtopic 205-40) (Topic 718): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”).
	The Update provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes.
	This Update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. Earlier adoption is permitted.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Financial_Condition

Financial Condition	3 Months Ended
	Sep. 30, 2014
Financial Conditions Disclosure [Abstract]	'
Financial Conditions Disclosure [Text Block]	'
	Note 3 - Financial Condition
	The Company’s financial statements for the interim period ended September 30, 2014 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business.  The Company has a deficit accumulated from inception.  In addition, the Company has not generated any revenues and no revenues are anticipated in the short-term.  Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs.  The Company has not yet commenced any product commercialization.  Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2014 the Company had cash and cash equivalents of $41,120,652. The Company has sufficient capital to continue its business, at least, through September 30, 2016, at the current rate of expenditure. The Company therefore would not be considered to have risks relative to its ability to continue as a going concern within the applicable guidelines.
	While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities.
	On July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 shall be calculated on a per diem basis from the Closing Date. The Company has the right, but not the obligation, to repay the Debenture prior to the Maturity Date (the “Redemption Payment”) in cash or, at the option of the Holder, a number of shares of the Company’s Common Stock. If the closing bid price of the Common Stock is in excess of $5.25 when the Company notifies the Holder it has elected to prepay the Debenture (the “Redemption Date”), the Company must redeem the Debenture by delivering to the Holder 951,381 shares of Common Stock and any unpaid coupon interest in lieu of a cash Redemption Payment. If the Holder elects to receive the Redemption Payment in cash, or if the closing bid price of the Common Stock is less than $5.25, the Company shall pay to the Holder a Redemption Payment in cash equal to the principal amount of the Debenture, plus any accrued coupon interest, and additional interest of 7% per annum for the period from the Closing Date to the Redemption Date. As additional interest on the Debenture, the Company shall issue 187,000 shares of its restricted Series A Preferred Stock (the “Series A”) to the Holder. Each shares of Series A votes at 9 votes per share. In addition, only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. The Offering was conducted directly by the Company without the use of a placement agent. Accordingly, no placement agent fees or other commissions were paid by the Company in connection with the Offering.
	On September 5, 2014, NanoViricides, Inc. (the “Company”) accepted notices to exercise old warrants (See Note 9, below.) for the purchase of an aggregate of 2,136,655 shares of the Company’s common stock at the exercise price of $3.50 per share for aggregate proceeds of $7,478,292.50. On July 17, 2014, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 shares of common stock underlying warrants previously issued by the Company in various private placement offerings between 2005 and September 2009 (the “Old Warrants”), as described more fully in the Form S-3 (the “Registered Warrants”). The Form S-3 was declared effective by the Securities and Exchange Commission on August 1, 2014. As of August 15, 2014, any Registered Warrants as specified above and not previously exercised have expired.
	As a result of the successful sale of the Company’s Common Shares, management believes that the Company has sufficient cash and cash equivalents to meet its budgeted expenditures through, at least, September 30, 2016 at current rate of expenditures.
	Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral nanomedicines.  The Company has not yet commenced any product commercialization.  The Company has incurred significant losses from operations since its inception, resulting in a an accumulated deficit of $(52,645,328) at September 30, 2014 and expects recurring losses from operations to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations.  There can be no assurance that the Company will achieve or maintain profitability in the future.  Despite the Company’s financings in 2014 and 2013 and a cash and cash equivalent balance of $41,120,652 at September 30, 2014, substantial additional financing will be required in future periods.  The Company may require additional capital to finance planned and currently unplanned capital costs, and additional staffing requirements during the next twenty four months.  The Company has, in the past, adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its Plan of Operations as necessary, if it is unable to raise such additional funds.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 4 - Related Party Transactions
	Related Parties
	Related parties with whom the Company had transactions are:
	Related Parties	Relationship
	Anil R. Diwan	Chairman, President, significant stockholder and director
	Eugene Seymour	CEO, Significant shareholder, Director
	TheraCour Pharma, Inc.	An entity owned and controlled by significant stockholder
	InnoHaven, LLC	An entity owned and controlled by significant stockholder
	Milton Boniuk, MD	Director and significant stockholder
	Fixed Assets
		September 30, 2014		June 30, 2014
	During the reporting period, InnoHaven, LLC, acquired fixed assets on behalf of the Company from third party vendors behalf of the Company at 1 Controls Drive, Shelton, Ct	$	-	$	4,500,000
	During the reporting Period, Thera Cour Pharma, Inc. acquired fixed assets on behalf of the Company from third party vendors	$	110,578	$	528,000
	Account Payable – Related Party
		September 30, 2014		June 30 , 2014
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc on the reporting date was	$	331,448	$	758,676
	Research and Development Costs Paid to Related Parties
		September		September 30,
		30, 2014		2013
	Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. As of September 30, 2014, pursuant to its license agreement, the Company has paid a security advance of $424,402 to and held by TheraCour Pharma, Inc. which is reflected in Prepaid Expenses. No royalties are due TheraCour from the Company’s inception through June 30, 2014.	$	769,185	$	924,125
	Long-Term Debentures Payable – Directors
		September 30, 2014		June 30, 2014
	On February 1, 2013, the Company raised $4M from a family investment office and a charitable foundation controlled by Dr. Milton Boniuk through the issuance of our Series B Debentures. The investors purchased unsecured convertible debentures with a 4-year term. The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal. The warrants are priced at $3.50 and will be valid for 3 years after issuance. The investors can convert the principal and any accrued interest into common stock at a fixed price of $3.50 per share. The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act.	$	4,000,000	$	4,000,000
	Repayments from inception to date		-		-
	Remaining balance		4,000,000		4,000,000
	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 has been accrued and will be paid over the remaining life of the Debenture commencing July 1, 2015.		5,000,000		5,000,000
	Repayments from inception to date		-		-
	Remaining balance		5,000,000		5,000,000
		$	9,000,000	$	9,000,000
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. . In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. (4) we will make royalty payments (calculated as a percentage of net sales of the licensed drugs) of 15% to TheraCour Pharma, Inc. (5) and agreed that TheraCour Pharma, Inc. retains the exclusive right to develop and manufacture the licensed drugs. TheraCour Pharma, Inc. agreed that it will manufacture the licensed drugs exclusively for NanoViricides, and unless such license is terminated, will not manufacture such product for its own sake or for others.

Concentrations

Concentrations	3 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	Note 5 - Concentrations
	Vendor purchase concentrations for September 30, 2014 and 2013 are as follows:
		Net Purchases						Accounts Payable
		For the three months ended September 30,						As of September  30,
		2014			2013			2014			2013
	TheraCour Pharma, Inc	769,185	45.6	%	924,126	48.9	%	331,448	68	%	1,139,825	73.6	%
	Kard Scientific, Inc.	-	0	%	247,660	13.1	%	123,570	25.4	%	246,963	16	%
	Total Purchases	1,687,133	100	%	1,888,782	100	%	487,426	100	%	1,547,883	100	%

Property_and_Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	N ote 6 - Property and Equipment
	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:
		September 30,		June 30,
		2014		2014
	GMP Facility	$	3,551,713	$	3,099,780
	Office Equipment		30,048		30,048
	Furniture and Fixtures		1,400		1,400
	Lab Equipment		3,716,093		3,605,514
	Total Property and Equipment		7,299,254		6,736,742
	Less Accumulated Depreciation		-1,291,318		-1,239,986
	Property and Equipment, Net	$	6,007,936	$	5,496,756
	Depreciation expenses for the three months ended September 30, 2014 and 2013 were $51,332 and $52,719, respectively.

Trademark_and_Patents

Trademark and Patents	3 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 7 - Trademark and Patents
	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:
		September 30,		June 30,
		2014		2014
	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-52,889		-50,696
	Trademarks and Patents, Net	$	406,065	$	408,258
	Amortization expense amounted to $2,193 and 2,193 for the three months ended September 30, 2014, and 2013, respectively.

Prepaid_Expenses

Prepaid Expenses	3 Months Ended
	Sep. 30, 2013
Prepaid Expenses [Abstract]	'
Prepaid Expenses Disclosure [Text Block]	'
	Note 8 - Prepaid Expenses
	Prepaid Expenses are summarized as follows:
		September 30,		June 30,
		2014		2014
	TheraCour Pharma, Inc.	$	424,402	$	709,221
	Prepaid Others		59,099		108,089
		$	483,501	$	817,310

Equity_Transactions

Equity Transactions	3 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 9 - Equity Transactions
	On September 5, 2014, NanoViricides, Inc. (the “Company”) accepted notices to exercise old warrants for the purchase of an aggregate of 2,136,655 shares of the Company’s common stock at the exercise price of $3.50 per share for aggregate proceeds of $7,478,292.50. On July 17, 2014, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 shares of common stock underlying warrants previously issued by the Company in various private placement offerings between 2005 and September 2009, (“old warrants”) as described more fully in the Form S-3 (the “Registered Warrants”). The Form S-3 was declared effective by the Securities and Exchange Commission on August 1, 2014. As of August 15, 2014, any Registered Warrants as specified above and not previously exercised have expired.
	Unregistered Securities
	On July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”).
	On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 Shares of its Series A Convertible Preferred stock to Dr. Milton Boniuk as additional interest, pursuant to the terms of the Debenture. The Company recognized a charge of $1,645,606 as a discount of the Series C Debenture which will be amortized over the remaining life of the Debenture under the straight line method. For the three months ended September 30, 2014 the Company recognized $102,850 amortization of this discount as a charge to “Discount on convertible debentures”.
	In August, 2014, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,148 shares of common stock at $5.02 per share expiring in August, 2018.  These warrants were valued at $22,292 and recorded as consulting expense.
	For the three months ended September 30, 2014, the Company’s Board of Directors authorized the issuance of 7,716 shares of its Series A Convertible Preferred stock for employee compensation. The Company recorded an expense of $72,980.
	For the three months ended September 30, 2014, the Company’s Board of Directors authorized the issuance of 2,059 shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $27,000.
	For the three months ended September 30, 2014, the Company’s Board of Directors authorized the issuance of 2,856 shares of its common stock with a restrictive legend for Director services. The Company recorded an expense of $11,250.
	The Company estimated the relative fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		August 15,
		2014
	Expected life (year)			4
	Expected volatility			91.68	%
	Expected annual rate of quarterly dividends			0	%
	Risk-free rate(s)			1.2	%
	There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a change of control of the Company. The Company, therefore, estimated the relative fair value of the Preferred A shares granted to various Employees on the date of grant. The Preferred Series A shares fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; ii) the value of the voting rights since the holder would lose the voting rights upon conversion. The conversion of the shares is triggered either by the Company or a Change of Control. The valuations of the Series A Preferred Stock as of 9/30/14 used the following inputs:
		a.	The common stock price (post-reverse split) was in the range $3.90 to $4.16;
		b.	54,614,930 to 56,450,000 shares outstanding and Series A Preferred shares with 2,572 (post–split 9/10/13) issued monthly ;
		c.	A 5.36% premium over the common shares for the voting preferences;
		d.	63,899,777 to 65,193,001 total voting shares and the monthly shares representing voting rights of 2.425% to 2.448% of the total;
		e.	The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 and a remaining restricted term of 2.59 to 2.42 years;
		f.	35.53% to 31.95% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 87.68% to 91.87% volatility, 0.47% to 0.58% risk free rate) applied to the converted common.

Stock_Options_and_Warrants

Stock Options and Warrants	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 10 - Stock Options and Warrants
	Stock Options
	In September 2005, 142,857 stock options were granted to Eugene Seymour, our CEO under an employment agreement.  Of these options, 71,429 were vested immediately and are exercisable from September 2005 until September 2015, and the remaining  options vested annually on January 1, 2007 and 2008 in two  equal amounts.
	In September 2005, 285,715 stock options were granted to Anil Diwan, our Chairman and President under an employment agreement.  Of these options, 95,238 were vested immediately and are exercisable from September 2005 until September, 2015, and the remaining options vested annually on January 1, 2007 and January 1, 2008 in two equal amounts.
	In September 2005, 142,857 stock options were granted to Leo Ehrlich, our former CFO under an employment agreement. Of these options, 71,429 were vested immediately and are exercisable from September 2005 until September 2015, and the remaining options vest annually in two equal amounts.   On May 16, 2007, Leo Ehrlich resigned as the Company’s Chief Financial Officer. At time of his resignation 107,143 options were vested and are exercisable from September 2005 until September 2015. The remaining options were forfeited.
	The Company has accounted for these options granted to officers under the provisions of paragraph 718-10-30 of the FASB Accounting Standards Codification” and after giving effect to the 3.5 to 1 reverse split of September 9, 2013. Based on fair market value of these options, $7,044 was recognized as stock based compensation expense for the years ended June 30, 2009.  For the three months ended September 30, 2014 and 2013, the Company did not record any compensation expense related to these options.
	The following table presents the combined activity of stock options issued for the reporting periods ended September 30, 2014 as follows:
	Stock Options		Number of	Weighted		Weighted		Aggregate
			Shares	Average		Average		Intrinsic
				Exercise Price		Remaining		Value ($)
				per share ($)		Contractual
						Term (years)
	Outstanding at June 30, 2014		535,715	0.35		1.23		2,094,643
	Granted		-	-		-		-
	Exercised		-	-		-		-
	Expired		-	-		-		-
	Canceled		-	-		-		-
	Outstanding at September 30,2014		535,715	0.35		0.98		1,451,780
	As of September 30, 2014 there was no unrecognized compensation cost.
	Stock Warrants
	Stock Warrants	Number of		Weighted		Weighted			Aggregate
		Shares		Average		Average			Intrinsic Value
				Exercise		Remaining			($)
				Price		Contractual Term
				per share		(years)
				($)
	Outstanding at June 30, 2014		8,894,355		5.01		2.78			2,278,458
	Granted		17,148		4.18		3.88			-
	Exercised		1,926,656		-		-			-
	Expired		1,059,616		-		-			-
	Canceled		-		-		-			-
	Outstanding at September 30,2014		5,925,231		5.15		3.86			113,571
	Of the above warrants, 277,143 expire in fiscal year ending June 30, 2015; and 68,571 expire in fiscal year ended June 30, 2016; 68,571 expire in fiscal year ending June 30, 2017; 127,487 in fiscal year ending June 30,2018; 5,383,460 in fiscal year ending June 30, 2019.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 11 - Commitments and Contingencies
	Operating Lease
	The Company’s principal executive offices are located at 135 Wood Street, West Haven, Connecticut, and include approximately 7,000 square feet of office and laboratory space at a base monthly rent of $8,695. The term of lease expired on February 28, 2011 and is now on a month-by-month basis.
	Total rent expense at 135 Wood Street, West Haven, Connecticut amounted to $26,085 and $26,085 for the three months ended September 30, 2014 and 2013, respectively.
	On February 11, 2013, the Company entered into a binding Memorandum of Understanding (“MOU”) with Inno-Haven, LLC, a Connecticut Limited Liability Company (“Inno-Haven”), to lease for a four-year term a 18,000 square foot building located at 1 Controls Drive, Shelton, Connecticut (the “Leased Premises”), and for Inno-Haven to initiate renovation of the facility at the Company’s direction. The Company has filled out and completed such renovations as it determined were necessary for its specific use as a laboratory and GMP clean room drug manufacturing. Inno-Haven is controlled by Anil Diwan, the Company’s founder, President and Chairman and controlling shareholder of TheraCour Pharma, Inc., the Company’s principal shareholder (“TheraCour”). The MOU is subject to a definitive lease agreement (the “Lease Agreement”) to be executed upon final determination of the cost of the laboratory and GMP clean room, and which would contain definitive terms regarding rent, taxes, utilities, maintenance and other, similar items. Pursuant to the MOU, the Company has agreed to provide up to $2,000,000 in cash collateral for sums borrowed by Inno-Haven (collectively, the “Loans”) to complete the build-out and renovation of the Leased Premises for the benefit of the Company. The Company agreed to file a registration statement for shares of its restricted Common Stock, provided by TheraCour Pharma, Inc., as additional collateral for any or all of the Loans (the “Registrable Shares”). The Company shall file a registration statement within ninety (90) days of a closing of a Loan (a “Closing”) to cover such Registrable Shares and use its best efforts to have such registration statement declared effective no later than one hundred eighty (180) days following the Closing, and keep such registration statement effective until the termination of the respective collateral agreement, upon request to do so by Inno-Haven. The MOU further provides that, so long as there is no breach of the Lease Agreement by the Company, any distribution of the collateral in accordance with a Loan will first be made from the proceeds of life insurance policies (if applicable), then from the proceeds of the sale of the Registrable Shares, and then, should there be any balance still owing to the lender, from the cash collateral.
	On February 11, 2013, pursuant to the provisions of the MOU, the Company transferred $1,000,000 as cash collateral (the “Cash Collateral”) and agreed to register a number of shares of the Company’s Common Stock, which shares were provided by TheraCour Pharma, Inc., equal to $1,000,000 (the “Collateral Shares”) as collateral pursuant to a Loan and Security Agreement entered into between Inno-Haven and a non-affiliated lender (the “Loan Agreement”) for a loan in the principal amount of $2,000,000. On September 17, 2013, The Company transferred the remaining $1,000,000 cash collateral to Inno-Haven. The value of the Collateral Shares shall be determined every three months and, in the event that the current number of shares of the Common Stock is less than $1,000,000, Inno-Haven may deposit, and the Company shall register, additional shares to equal the aforesaid $1,000,000. Alternatively, Inno-Haven may deposit cash equal to the difference between $1,000,000 and the value of the Collateral Shares. Moreover, Inno-Haven is required to obtain a life insurance policy to insure the life of Dr. Diwan in the amount of $2,000,000. If Dr. Diwan dies during the term of the Loan Agreement, the lender shall have the option to demand payment of the balance of the loan, but, shall be repaid first from the proceeds of any life insurance policy (if applicable), then from the proceeds of the sale of the Collateral Shares, and then, should there be any balance still owing to the lender, from the Cash Collateral. As of September 30, 2014, the Company has utilized approximately $4.5 million for specific fixtures and improvements it required for the new laboratory and cGMP facilities.
	No lease agreement has been perfected with Inno-Haven to date. The Company engaged external consultants to help determine whether to lease this facility or to purchase it outright from Inno-Haven. Subsequently, the Company’s Board of Directors has authorized the acquisition of 1 Controls Drive from Inno-Haven in an amount equal to its costs in acquiring and fitting out 1 Controls Drive on the Company’s behalf.
	Total rent expense paid to Inno-Haven during this period amounted to $-0- for the Three months ended September 30, 2014 and $-0- since February 11, 2013.
	Legal Proceedings
	On or about January 18, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-654437-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”).  The Complaint seeks to compel inspection of the Company’s books and records.  On or about February 14, 2012 we filed a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted.  The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which it is not entitled.  The Complaint by a holder of less than 1 percent of the common stock of the Company seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute.  Management believes that this lawsuit has no merit or basis and intends to vigorously defend it.  Monetary damages have not been claimed and as a result no accrual has been made in relation to this litigation. On April 9, 2012, the Court dismissed the Complaint for failure to state a Claim for which relief could be granted.
	On or about April 13, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-659535-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”). The Complaint seeks to compel inspection of the Company’s books and records. On or about May 2, 2012, the Company filed a Demand for Security of Costs. Upon filing of the Demand, proceedings relative to the Company are stayed pending posting of the demanded security (or plaintiff engages in motion practice about the Demand). The Company may seek dismissal of the complaint if plaintiff has not posted the demanded security (or engaged the court). The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which the Company believes it is not entitled. The Complaint, by a holder of less than 1 percent of the common stock of the Company, seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute. On or about July 18, 2012, the Plaintiff moved to amend its answer. On or about August 8, 2012, we filed our opposition to Plaintiff’s Motion to Amend and a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted. On or about September 13, 2012 the court granted the Plaintiff’s Motion to Amend. On or about September 17, 2012 the Plaintiff served its “Second Amended Shareholder Derivative Complaint” upon our Counsel in Nevada. As in the prior two complaints that this Plaintiff has filed in this action, the Second Amended Complaint sought to compel inspection of the Company’s books and records, sought injunctive relief, an accounting and alleges breach of Fiduciary by Dr. Seymour and Dr. Diwan. On or about October 11, 2012, we filed a Motion to Dismiss the Second Amended Complaint for failure to state a claim upon which relief can be granted. On or about December 4, 2012, the Court granted the Company’s Motion to Dismiss with respect to Dr. Seymour and Dr. Diwan and ordered the case dismissed as to all claims but the Plaintiff’s request to compel documents required to be maintained by the Company’s registered agent in Nevada pursuant to NRS 78.105. On or about December 26, 2012, the Company provided the Plaintiff with each of the documents to which it is entitled. Management believes that the Plaintiff does not have a legal or good faith basis for inspection or copying of its shareholder’s list and intends to vigorously defend the production thereof. In May, 2013, the Plaintiff filed a motion for permission to file a third amended complaint. The Company subsequently filed a motion to dismiss and for Summary Judgment. The Court denied the Motion to Dismiss and for Summary Judgment and ordered the Plaintiff to file its Third Amended Complaint. On or about July 15, 2013 the Company Petitioned the Nevada Supreme Court for a Writ of Prohibition or Mandamus reversing the trial Court’s denial of Summary Judgment. Thereafter, on or about September 20, 2013, the Nevada Supreme Court denied the Company’s Writ Petition. The Company filed its answer to the Third Amended Complaint, which contains only one cause of action which is identical to the sole cause of action which was not dismissed from the Second Amended Complaint. Specifically, the Third Amended Complaint seeks only to compel production of books and records required to be maintained by the Company’s Registered Agent pursuant to NRS 78.105 Management believes that the Company’s registered Agent has provided the Plaintiff with all documents to which it is entitled pursuant to NRS 78.105 and that this lawsuit has no merit or basis. The Company has vigorously defended this lawsuit. Following cross-motions for summary judgment and certain discovery as limited by the court, the parties engaged in a settlement conference in March 2014, at which time an agreement was reached resolving the parties’ disputes in this matter. Pursuant to the Settlement Agreement, the Company deposited $150,000 with its attorney to be released to reimburse the Plaintiff for a portion of its litigation expenses. However, disagreements later arose regarding the negotiated resolution, precipitating, among other things, the Company’s application for court intervention and repeated status hearings. Final settlement documents were fully exchanged on September 11, 2014. Upon the Plaintiff’s compliance with the terms of the Settlement Agreement, the Company authorized counsel to release the reimbursement amount to the Plaintiff. An order dismissing the foregoing lawsuit was entered on September 16, 2014.
	On or about July 15, 2013 the same Plaintiff that had filed the repetitive complaints in the Nevada action as set forth in the preceding paragraphs (Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc.) filed a Shareholder Derivative complaint with the United States District Court for the District of Colorado.  The Plaintiff asserted the action is a shareholder derivative action and the Company is solely a nominal defendant.  The Company maintains that it, as well as the individual defendants, Messrs. Seymour and Diwan, have not been served in the action. However, a default was filed against the Company, which has been vacated. The Complaint alleges that the Company has failed to deliver information requested by the Plaintiff, the identical information the Plaintiff is seeking inspection of in the Nevada action, and that the individual defendants, Messrs. Seymour and Diwan, breached their fiduciary duties to the Company and caused it financial harm.  The Plaintiff demanded an order to inspect the Company’s records, an order revoking Messrs. Diwan and Seymour from the Board of Directors, equitable relief, and consequential and punitive damages.  The Company believes these claims had no merit and defended this action vigorously. The Company moved the District Court to dismiss the action in its entirety. No facts have been submitted to support the claimed vague consequential and punitive damages. Management has determined that such claims are specious and not relevant to the Company and no accrual has been made in relation to this litigation. The action was settled and dismissed with prejudice pursuant to the Settlement Agreement in the above referenced Nevada action. Similarly, upon the Plaintiff’s compliance with the terms of the Settlement Agreement, the Company authorized counsel to release the reimbursement amount to the Plaintiff. An order dismissing the foregoing lawsuit was entered on September 16, 2014.
	There are no other legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company.

Subsequent_Events

Subsequent Events	3 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 12 - Subsequent Events
	Management has evaluated all events that occurred after the balance sheet date through the date when these financial statements were issued to determine if they must be reported. The Management of the Company has determined that the following reportable subsequent event is required to be disclosed:
	On October 31, 2014, the Company filed a Registration Statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”).  The Registration Statement is a “universal” shelf registration statement for the registration of up to $50 million of our common stock, preferred stock, warrants, debt securities and units comprised of any or all of such securities.  If and when the Registration Statement is declared effective, the Company will be able to offer and sell, from time to time, up to $50 million of securities, including shares of the Company’s common stock and preferred stock, debt securities, warrants, and units, the terms of which will be described in prospectus supplements filed with the Commission, as applicable.  Such securities may not be sold, nor may offers to buy be accepted, until the Registration Statement is declared effective by the Commission

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation – Interim Financial Information
	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management,   considered necessary for a fair presentation of the results for the interim periods presented.  Interim results are not necessarily indicative of the results for the full year.  The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s form 10-K for the fiscal year ended June 30, 2014 filed with the SEC on September 30, 2014.
	For a summary of significant accounting policies (which have not changed from June 30, 2014), see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Income (Loss) per Common Share
	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the	For the Fiscal
		Three Months	Year
		Ended	Ended
		September 30, 2014	September 30, 2013
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.35 per share expiring ten (10) years from the date of issuance	535,715	535,715
	Sub-total: stock options	535,715	535,715
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007  to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	466,486
	Warrants issued from June 15, 2008 through May 15, 2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2015	211,429	211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015	65,714	65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016	68,571	68,571
	Warrants issued from August 16, 2012 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017	68,571	68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through September 30, 2014	2,810,071	2,910,071
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017	17,143	17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018	58,910	58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017	17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $5.25 per share expiring January 24, 2019	76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018	17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018	17148
	Warrants issued on August 15, 2014 to SAB for services with an exercise price of $5.02 per share expiring on August 15, 2018	17,148
	Sub-total: warrants	5,925,231	6,386,680
	Total potentially outstanding dilutive common shares	6,460,946	6,922,395
	In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
	At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,960,785 based upon the Selling price of the Company’s common stock on September 30, 2014 of $3.06. At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,142,858.
	The Company has also issued 3,387,795 of $0.001 par value Convertible Preferred A shares to investors and others. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At September 30, 2014, the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into, is 11,857,283.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
	The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
	The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	The company has limited operations and is considered to be in the development stage. The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage. The Company adopted this guidance from June 30, 2014
	In June 2014, the FASB issued the FASB Accounting Standards Update No. 2014-12 “Compensation—Stock Compensation (Topic 718) : Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).
	The amendments clarify the proper method of accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period.  The Update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition.  The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015.  Earlier adoption is permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements— Going Concern (Subtopic 205-40) (Topic 718): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”).
	The Update provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes.
	This Update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. Earlier adoption is permitted.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the	For the Fiscal
		Three Months	Year
		Ended	Ended
		September 30, 2014	September 30, 2013
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.35 per share expiring ten (10) years from the date of issuance	535,715	535,715
	Sub-total: stock options	535,715	535,715
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007  to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	466,486
	Warrants issued from June 15, 2008 through May 15, 2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2015	211,429	211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015	65,714	65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016	68,571	68,571
	Warrants issued from August 16, 2012 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017	68,571	68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through September 30, 2014	2,810,071	2,910,071
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017	17,143	17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018	58,910	58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017	17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $5.25 per share expiring January 24, 2019	76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018	17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018	17148
	Warrants issued on August 15, 2014 to SAB for services with an exercise price of $5.02 per share expiring on August 15, 2018	17,148
	Sub-total: warrants	5,925,231	6,386,680
	Total potentially outstanding dilutive common shares	6,460,946	6,922,395

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Fixed Assets
		September 30, 2014		June 30, 2014
	During the reporting period, InnoHaven, LLC, acquired fixed assets on behalf of the Company from third party vendors behalf of the Company at 1 Controls Drive, Shelton, Ct	$	-	$	4,500,000
	During the reporting Period, Thera Cour Pharma, Inc. acquired fixed assets on behalf of the Company from third party vendors	$	110,578	$	528,000
	Account Payable – Related Party
		September 30, 2014		June 30 , 2014
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc on the reporting date was	$	331,448	$	758,676
	Research and Development Costs Paid to Related Parties
		September		September 30,
		30, 2014		2013
	Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. As of September 30, 2014, pursuant to its license agreement, the Company has paid a security advance of $424,402 to and held by TheraCour Pharma, Inc. which is reflected in Prepaid Expenses. No royalties are due TheraCour from the Company’s inception through June 30, 2014.	$	769,185	$	924,125
	Long-Term Debentures Payable – Directors
		September 30, 2014		June 30, 2014
	On February 1, 2013, the Company raised $4M from a family investment office and a charitable foundation controlled by Dr. Milton Boniuk through the issuance of our Series B Debentures. The investors purchased unsecured convertible debentures with a 4-year term. The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal. The warrants are priced at $3.50 and will be valid for 3 years after issuance. The investors can convert the principal and any accrued interest into common stock at a fixed price of $3.50 per share. The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act.	$	4,000,000	$	4,000,000
	Repayments from inception to date		-		-
	Remaining balance		4,000,000		4,000,000
	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 has been accrued and will be paid over the remaining life of the Debenture commencing July 1, 2015.		5,000,000		5,000,000
	Repayments from inception to date		-		-
	Remaining balance		5,000,000		5,000,000
		$	9,000,000	$	9,000,000

Concentrations_Tables

Concentrations (Tables)	3 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
	Vendor purchase concentrations for September 30, 2014 and 2013 are as follows:
		Net Purchases						Accounts Payable
		For the three months ended September 30,						As of September  30,
		2014			2013			2014			2013
	TheraCour Pharma, Inc	769,185	45.6	%	924,126	48.9	%	331,448	68	%	1,139,825	73.6	%
	Kard Scientific, Inc.	-	0	%	247,660	13.1	%	123,570	25.4	%	246,963	16	%
	Total Purchases	1,687,133	100	%	1,888,782	100	%	487,426	100	%	1,547,883	100	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:
		September 30,		June 30,
		2014		2014
	GMP Facility	$	3,551,713	$	3,099,780
	Office Equipment		30,048		30,048
	Furniture and Fixtures		1,400		1,400
	Lab Equipment		3,716,093		3,605,514
	Total Property and Equipment		7,299,254		6,736,742
	Less Accumulated Depreciation		-1,291,318		-1,239,986
	Property and Equipment, Net	$	6,007,936	$	5,496,756

Trademark_and_Patents_Tables

Trademark and Patents (Tables)	3 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:
		September 30,		June 30,
		2014		2014
	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-52,889		-50,696
	Trademarks and Patents, Net	$	406,065	$	408,258

Prepaid_Expenses_Tables

Prepaid Expenses (Tables)	3 Months Ended
	Sep. 30, 2014
Prepaid Expenses [Abstract]	'
Schedule Of Prepaid Expenses [Table Text Block]	'
	Prepaid Expenses are summarized as follows:
		September 30,		June 30,
		2014		2014
	TheraCour Pharma, Inc.	$	424,402	$	709,221
	Prepaid Others		59,099		108,089
		$	483,501	$	817,310

Equity_Transactions_Tables

Equity Transactions (Tables)	3 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders Equity [Table Text Block]	'
	The Company estimated the relative fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		August 15,
		2014
	Expected life (year)		4
	Expected volatility		91.68	%
	Expected annual rate of quarterly dividends		0	%
	Risk-free rate(s)		1.2	%

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	3 Months Ended
	Sep. 30, 2014
Equity Option [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table presents the combined activity of stock options issued for the reporting periods ended September 30, 2014 as follows:
	Stock Options		Number of	Weighted		Weighted		Aggregate
			Shares	Average		Average		Intrinsic
				Exercise Price		Remaining		Value ($)
				per share ($)		Contractual
						Term (years)
	Outstanding at June 30, 2014		535,715	0.35		1.23		2,094,643
	Granted		-	-		-		-
	Exercised		-	-		-		-
	Expired		-	-		-		-
	Canceled		-	-		-		-
	Outstanding at September 30,2014		535,715	0.35		0.98		1,451,780
Stock Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	As of September 30, 2014 there was no unrecognized compensation cost.
	Stock Warrants
	Stock Warrants	Number of		Weighted		Weighted			Aggregate
		Shares		Average		Average			Intrinsic Value
				Exercise		Remaining			($)
				Price		Contractual Term
				per share		(years)
				($)
	Outstanding at June 30, 2014		8,894,355		5.01		2.78			2,278,458
	Granted		17,148		4.18		3.88			-
	Exercised		1,926,656		-		-			-
	Expired		1,059,616		-		-			-
	Canceled		-		-		-			-
	Outstanding at September 30,2014		5,925,231		5.15		3.86			113,571

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Details Textual) (USD $)	0 Months Ended	3 Months Ended		113 Months Ended	3 Months Ended
	Feb. 15, 2010	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Feb. 15, 2010
				ECMM [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]
Organization and Nature of Business [Line Items]	'	'	'	'	'	'
Entity Incorporation, State Country Name	'	'Colorado	'	'	'	'
Entity Incorporation, Date Of Incorporation	'	25-Jul-00	'	'	'	'
Business Acquisition, Name of Acquired Entity	'	'Edot-com.com, Inc.	'	'	'	'
Business Acquisition, Date of Acquisition Agreement	'	12-May-05	'	'	'	'
Common Stock Shares Issued Prorata Basis	'	'	'	4,000	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	80,000,000	'	'
Common stock, shares issued	'	56,535,135	54,620,993	100,000,000	'	'
Common stock, shares, outstanding	'	56,535,135	54,620,993	100,000,000	'	'
Business Acquisition, Percentage of Voting Interests Acquired	'	'	'	80.00%	'	'
Preferred stock, shares issued	'	'	'	'	'	2,000,000
Preferred stock	'	'	'	'	'	$2,000
Convertible Preferred Stock, Terms of Conversion	'	'Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition.	'	'	'The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock	'
Stockholders' Equity, Reverse Stock Split	'(adjusted for the 3.5 to 1 reverse split)	'	'	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,460,946	6,922,395
Employee Stock Option [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Total Stock Option [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Warrants Issued One [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	513,143
Warrants Issued Two [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	466,486
Warrants Issued Three [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	211,429	211,429
Warrants Issued Four [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	568,771
Warrants Issued Five [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,437,871
Warrants Issued Six [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	65,714	65,714
Warrants Issued Seven [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571
Warrants Issued Eight [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571
Warrants Issued Nine [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,810,071	2,910,071
Warrants Issued Ten [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	17,143
Warrants Issued Eleven [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,910	58,910
Warrants Issued Twelve [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	'
Warrants Issued Thirteen [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,479,935	'
Warrants Issued Fourteen [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	76,306	'
Warrants Issued Fifteen [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	'
Warrants Issued Sixteen [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,148	'
Warrants Issued Seventeen [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,148	'
Total Warrants [Member]	'	'
Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,925,231	6,386,680

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Accounting Policies [Line Items]	'	'
Common Stock, Par Or Stated Value Per Share	$0.00	$0.00
Debt Conversion, Converted Instrument, Shares Issued	1,960,785	'
Debt Interest Conversion Converted Instrument Shares Issued	1,142,858	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$0.35	'
Share Based Compensation Arrangement By Share Based Payment Award Expiration Term	'10 years	'
Warrants Exercise Price	$6.05	'
Convertible Preferred Stock, Terms Of Conversion	'Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition.	'
Series A Convertible Preferred Stock [Member]	'	'
Accounting Policies [Line Items]	'	'
Preferred Stock, Shares Issued	3,387,795	3,193,079
Common Stock [Member]	'	'
Accounting Policies [Line Items]	'	'
Common Stock, Par Or Stated Value Per Share	$3.06	'
Convertible Preferred Stock, Shares Issued upon Conversion	11,857,283	'
June 15,2006 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$3.50	'
Warrants Expiration Date	15-Aug-14	'
August 22, 2008 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$3.50	'
Warrants Expiration Date	15-Aug-14	'
June 15, 2008 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Expiration Date	28-Feb-15	'
June 30, 2009 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$3.50	'
Warrants Expiration Date	15-Aug-14	'
September 30, 2009 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$3.50	'
Warrants Expiration Date	15-Aug-14	'
August 16 2010 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Expiration Date	30-Jun-15	'
August 16 2011 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Expiration Date	30-Jun-16	'
August 16 2012 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$5.17	'
Warrants Expiration Date	30-Jun-17	'
September 10, 2013 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$5.25	'
Warrants Expiration Date	10-Sep-18	'
September 10, 2013 [Member] | Placement Agents [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$5.25	'
Warrants Expiration Date	10-Sep-18	'
August 15, 2013 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$5.17	'
Warrants Expiration Date	15-Aug-17	'
November 15, 2013 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$6.56	'
Warrants Expiration Date	15-Nov-17	'
January 24, 2014 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$6.05	'
Warrants Expiration Date	24-Jan-19	'
January 24, 2014 [Member] | Placement Agents [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$5.25	'
Warrants Expiration Date	24-Jan-19	'
February 14, 2014 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$3.98	'
Warrants Expiration Date	14-Feb-18	'
May 15, 2014 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$4.11	'
Warrants Expiration Date	15-May-18	'
August 15 2014 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$5.02	'
Warrants Expiration Date	15-Aug-18	'
Minimum [Member] | June 15, 2008 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$2.45	'
Minimum [Member] | August 16 2010 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$5.15	'
Minimum [Member] | August 16 2011 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$2.80	'
Maximum [Member] | June 15, 2008 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$9.38	'
Maximum [Member] | August 16 2010 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$6.34	'
Maximum [Member] | August 16 2011 [Member]	'	'
Accounting Policies [Line Items]	'	'
Warrants Exercise Price	$4.94	'

Financial_Condition_Details_Te

Financial Condition (Details Textual) (USD $)

0 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

Jul. 02, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Sep. 05, 2014

Sep. 30, 2014

Jul. 17, 2014

Sep. 30, 2014

Jul. 02, 2014

Jun. 30, 2014

Sep. 30, 2014

Registered Warrants [Member]

Registered Warrants [Member]

Registered Warrants [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Director [Member]

Financial Condition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

$41,120,652

$36,696,892

$19,200,882

$13,923,245

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

'

$0.00

$0.00

'

'

'

'

'

'

'

'

$0.00

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

$5.25

Long-Term Debt, Excluding Current Maturities

'

'

'

'

'

'

'

'

'

'

5,000,000

5,000,000

Derivative, Cap Interest Rate

'

'

'

'

'

'

'

'

'

10.00%

'

10.00%

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

2,136,655

2,136,655

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

$3.50

'

'

'

'

'

$3.50

Proceeds from Warrant Exercises

'

'

'

'

'

7,478,292.50

7,478,292.50

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

3,071,986

'

3,071,986

'

'

'

'

Retained Earnings (Accumulated Deficit)

'

$52,645,328

$52,406,258

'

'

'

'

'

'

'

'

'

Derivative, Description of Terms

'The Company has the right, but not the obligation, to repay the Debenture prior to the Maturity Date (the Redemption Payment) in cash or, at the option of the Holder, a number of shares of the Companys Common Stock. If the closing bid price of the Common Stock is in excess of $5.25 when the Company notifies the Holder it has elected to prepay the Debenture (the Redemption Date), the Company must redeem the Debenture by delivering to the Holder 951,381 shares of Common Stock and any unpaid coupon interest in lieu of a cash Redemption Payment. If the Holder elects to receive the Redemption Payment in cash, or if the closing bid price of the Common Stock is less than $5.25, the Company shall pay to the Holder a Redemption Payment in cash equal to the principal amount of the Debenture, plus any accrued coupon interest, and additional interest of 7% per annum for the period from the Closing Date to the Redemption Date. As additional interest on the Debenture, the Company shall issue 187,000 shares of its restricted Series A Preferred Stock (the Series A) to the Holder. Each shares of Series A votes at 9 votes per share. In addition, only in the event of a change of control of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A change of control is defined as an event in which the Companys shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. The Offering was conducted directly by the Company without the use of a placement agent. Accordingly, no placement agent fees or other commissions were paid by the Company in connection with the Offering.

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

30-Jun-18

'

'

'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

3 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Innohaven, LLC [Member]

Innohaven, LLC [Member]

TheraCour Pharma, Inc [Member]

TheraCour Pharma, Inc [Member]

TheraCour Pharma, Inc [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Due from Related Parties

'

'

'

'

'

'

'

$0

$4,500,000

$110,578

'

$528,000

Net Account Payable to related party

'

'

'

'

'

'

'

'

'

331,448

'

758,676

Research and development

811,107

1,174,221

'

'

'

'

'

'

'

769,185

924,125

'

Due to Related Parties, Noncurrent

'

'

'

4,000,000

4,000,000

5,000,000

5,000,000

'

'

'

'

'

Payments to Fund Long-term Loans to Related Parties

'

'

'

0

0

0

0

'

'

'

'

'

Due to Related Parties, Noncurrent

'

'

'

4,000,000

4,000,000

5,000,000

5,000,000

'

'

'

'

'

Due to Related Parties

$9,000,000

'

$9,000,000

'

'

'

'

'

'

'

'

'

Related_Party_Transactions_Det1

Related Party Transactions (Details Textual) (USD $)	3 Months Ended				3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Jul. 02, 2014	Jun. 30, 2014	Sep. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2014
			Long-Term Debentures Payable [Member]	Long-Term Debentures Payable [Member]	Long-Term Debentures Payable [Member]	Long-Term Debentures Payable [Member]	Long-Term Debentures Payable [Member]	Long-Term Debentures Payable [Member]	Long-Term Debentures Payable [Member]	Long-Term Debentures Payable [Member]	TheraCour Pharma, Inc [Member]
					Director [Member]	Director [Member]	Director [Member]	Director [Member]	Director [Member]	Director [Member]
								Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Related Party Transaction, Description of Transaction	'charge its costs (direct and indirect) plus no more than 30% of direct costs	'	'	'	'	'	'	'	'	'	'
Lab Supplies and Chemicals Fees	$25,000	'	'	'	'	'	'	'	'	'	'
Other General and Administrative Expense	2,000	'	'	'	'	'	'	'	'	'	'
Royalty Payment Percentage Of Net Sales	15.00%	'	'	'	'	'	'	'	'	'	'
Security Deposit	1,000,000	1,000,000	'	'	'	'	'	'	'	'	424,402
Due to Related Parties, Noncurrent	'	'	'	'	4,000,000	4,000,000	4,000,000	5,000,000	5,000,000	5,000,000	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	8.00%	'	'	'	'	'	'
Debt Instrument, Interest Rate Terms	'	'	'	'	'The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal.	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	'	'	'	$3.50	'	'	'	'	'	'
Debt Instrument, Term	'	'	'	'	'3 years	'	'	'	'	'	'
Debt Instrument, Basis Spread on Variable Rate	'	'	'	'	7.00%	'	'	'	'	'	'
Long-Term Debt, Excluding Current Maturities	'	'	'	$5,000,000	$5,000,000	'	'	$5,000,000	'	'	'
Derivative, Cap Interest Rate	'	'	10.00%	'	10.00%	'	'	10.00%	'	'	'
Common Stock, Par Or Stated Value Per Share	$0.00	$0.00	'	'	$0.00	'	'	$0.00	'	'	'
Debt Instrument, Convertible, Conversion Price	'	'	'	'	$5.25	'	'	$5.25	'	'	'

Concentrations_Details

Concentrations (Details) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Supplier Concentration Risk [Member]	'	'
Concentration Risk [Line Items]	'	'
Net Purchases	$1,687,133	$1,888,782
Accounts Payable	487,426	1,547,883
Supplier Concentration Risk [Member] | TheraCour Pharma, Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Net Purchases	769,185	924,126
Accounts Payable	331,448	1,139,825
Supplier Concentration Risk [Member] | Kard Scientific Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Net Purchases	0	247,660
Accounts Payable	$123,570	$246,963
Net Purchases [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	100.00%	100.00%
Net Purchases [Member] | TheraCour Pharma, Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	45.60%	48.90%
Net Purchases [Member] | Kard Scientific Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	0.00%	13.10%
Accounts Payable [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	100.00%	100.00%
Accounts Payable [Member] | TheraCour Pharma, Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	68.00%	73.60%
Accounts Payable [Member] | Kard Scientific Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	25.40%	16.00%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
Property, Plant and Equipment [Line Items]	'	'
GMP Facility	$3,551,713	$3,099,780
Office Equipment	30,048	30,048
Furniture and Fixtures	1,400	1,400
Lab Equipment	3,716,093	3,605,514
Total Property and Equipment	7,299,254	6,736,742
Less Accumulated Depreciation	-1,291,318	-1,239,986
Property and Equipment, Net	$6,007,936	$5,496,756

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
Depreciation	$51,332	$52,719

Trademark_and_Patents_Details

Trademark and Patents (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
Trademarks And Patents [Line Items]	'	'
Trademarks and Patents	$458,954	$458,954
Less Accumulated Amortization	-52,889	-50,696
Trademarks and Patents, Net	$406,065	$408,258

Trademark_and_Patents_Details_

Trademark and Patents (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Trademarks And Patents [Line Items]	'	'
Amortization	$2,193	$2,193

Prepaid_Expenses_Details

Prepaid Expenses (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
Prepaid Expense	$483,501	$817,310
Prepaid Others	59,099	108,089
TheraCour Pharma, Inc [Member]	'	'
Prepaid Expense	$424,402	$709,221

Equity_Transactions_Details

Equity Transactions (Details)	0 Months Ended
	Aug. 15, 2014
Class of Stock [Line Items]	'
Expected life (year)	'4 years
Expected volatility	91.68%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.20%

Equity_Transactions_Details_Te

Equity Transactions (Details Textual) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

Sep. 09, 2013

Aug. 31, 2014

Sep. 30, 2014

Sep. 30, 2013

Jul. 02, 2014

Sep. 05, 2014

Sep. 30, 2014

Jul. 17, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jul. 02, 2014

Long-Term Debentures Payable [Member]

Registered Warrants [Member]

Registered Warrants [Member]

Registered Warrants [Member]

Preferred Series A shares [Member]

Director [Member]

Director [Member]

Consulting Services [Member]

Subsequent Event [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Long-Term Debentures Payable [Member]

Director [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued to a Director for services rendered (in shares)

'

'

'

'

'

'

'

'

'

2,856

'

2,059

'

7,716

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants

'

17,148

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Price Per Share

'

$5.02

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Common Stock Warrant Issued During Period For Consulting Services

'

$22,292

'

'

'

'

'

'

'

$11,250

'

$27,000

'

$72,980

'

Warrants Exercise Period

'

'August, 2018

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note, Stock Split, Conversion Ratio

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Measurements, Significant Assumptions

'

'

'

'

'

'

'

'

'a. The common stock price (post-reverse split) was in the range $3.90 to $4.16; b. 54,614,930 to 56,450,000 shares outstanding and Series A Preferred shares with 2,572 (post–split 9/10/13) issued monthly ; c. A 5.36% premium over the common shares for the voting preferences; d. 63,899,777 to 65,193,001 total voting shares and the monthly shares representing voting rights of 2.425% to 2.448% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 and a remaining restricted term of 2.59 to 2.42 years; f. 35.53% to 31.95% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 87.68% to 91.87% volatility, 0.47% to 0.58% risk free rate) applied to the converted common.

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

2,136,655

2,136,655

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

3,071,986

'

3,071,986

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

$3.50

'

'

'

'

$3.50

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

'

'

7,478,292.50

7,478,292.50

'

'

'

'

'

'

'

'

Long-term Debt

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

Derivative, Cap Interest Rate

'

'

'

'

10.00%

'

'

'

'

'

10.00%

'

10.00%

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

1,960,785

'

'

'

'

'

'

'

'

'

'

'

187,000

Debt Instrument, Unamortized Discount (Premium), Net

'

'

'

'

1,645,606

'

'

'

'

'

'

'

'

'

'

Discount On Convertible Debentures

'

'

$260,578

$135,481

$102,850

'

'

'

'

'

'

'

'

'

'

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price per share , Outstanding	$0.35	'
Equity Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Outstanding	535,715	'
Number of Shares, Granted	0	'
Number of Shares, Exercised	0	'
Number of Shares, Expired	0	'
Number of Shares, Canceled	0	'
Number of Shares, Outstanding	535,715	535,715
Weighted Average Exercise Price per share , Outstanding	$0.35	'
Weighted Average Exercise Price per share, Granted	$0	'
Weighted Average Exercise Price per share, Exercised	$0	'
Weighted Average Exercise Price per share, Expired	$0	'
Weighted Average Exercise Price per share, Canceled	$0	'
Weighted Average Exercise Price per share , Outstanding	$0.35	$0.35
Weighted Average Remaining Contractual Term, (year) Outstanding	'11 months 23 days	'1 year 2 months 23 days
Aggregate Intrinsic Value, Outstanding	$2,094,643	'
Aggregate Intrinsic Value, Outstanding	$1,451,780	$2,094,643

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 1) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price per share , Outstanding	$0.35	'
Stock Warrants [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Outstanding	8,894,355	'
Number of Shares, Granted	17,148	'
Number of Shares, Exercised	1,926,656	'
Number of Shares, Expired	1,059,616	'
Number of Shares, Canceled	0	'
Number of Shares, Outstanding	5,925,231	8,894,355
Weighted Average Exercise Price per share , Outstanding	$5.01	'
Weighted Average Exercise Price per share, Granted	$4.18	'
Weighted Average Exercise Price per share, Exercised	$0	'
Weighted Average Exercise Price per share, Expired	$0	'
Weighted Average Exercise Price per share, Canceled	$0	'
Weighted Average Exercise Price per share , Outstanding	$5.15	$5.01
Weighted Average Remaining Contractual Term, (year) Granted	'3 years 10 months 17 days	'
Weighted Average Remaining Contractual Term, (year) Outstanding	'3 years 10 months 10 days	'2 years 9 months 11 days
Aggregate Intrinsic Value, Outstanding	$2,278,458	'
Aggregate Intrinsic Value, Outstanding	$113,571	$2,278,458

Stock_Options_and_Warrants_Det2

Stock Options and Warrants (Details Textual) (USD $)	12 Months Ended	3 Months Ended					1 Months Ended
	Jun. 30, 2009	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2005	Sep. 30, 2005	Sep. 30, 2005	16-May-07
		June 30, 2015 [Member]	June 30, 2016 [Member]	June 30, 2017 [Member]	June 30, 2019 [Member]	June 30 2018 [Member]	Chief Executive Officer [Member]	President [Member]	Chief Financial Officer [Member]	Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Warrants Exercisable	'	277,143	68,571	68,571	5,383,460	127,487	'	'	'	'
Warrants Expiration Date	'	30-Jun-15	30-Jun-16	30-Jun-17	30-Jun-19	30-Jun-18	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	'	'	'	'	142,857	285,715	142,857	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	'	'	'	'	'	'	71,429	95,238	71,429	107,143
Allocated Share-based Compensation Expense	$7,044	'	'	'	'	'	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	3 Months Ended				0 Months Ended	1 Months Ended	3 Months Ended
	Feb. 28, 2011	Sep. 30, 2014	Sep. 30, 2013	Feb. 11, 2013	Feb. 11, 2013	Feb. 11, 2013	Sep. 30, 2013	Sep. 30, 2014	Sep. 17, 2013
	sqft				TheraCour Pharma, Inc [Member]	Inno Haven [Member]	Inno Haven [Member]	Inno Haven [Member]	Inno Haven [Member]
						sqft
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'	'
Space For Office and Laboratory	7,000	'	'	'	'	'	'	'	'
Monthly Base Rent	$8,695	'	'	'	'	'	'	'	'
Lease Expiration Date	28-Feb-11	'	'	'	'	'	'	'	'
Operating Leases, Rent Expense, Net	'	26,085	26,085	'	'	0	'	0	'
Area of Land	'	'	'	'	'	18,000	'	'	'
Cash Collateral for Borrowed Securities	'	'	'	1,000,000	1,000,000	2,000,000	'	'	2,000,000
Securities Received as Collateral	'	'	'	'	'	'	'	'	1,000,000
Securities Owned and Pledged as Collateral, Description	'	'	'	'	'	'	'The value of the Collateral Shares shall be determined every three months and, in the event that the current number of shares of the Common Stock is less than $1,000,000, Inno-Haven may deposit, and the Company shall register, additional shares to equal the aforesaid $1,000,000. Alternatively, Inno-Haven may deposit cash equal to the difference between $1,000,000 and the value of the Collateral Shares.	'	'
Debt Instrument, Annual Principal Payment	'	'	'	2,000,000	'	'	'	'	'
Fixtures And Improvements	'	4,500,000	'	'	'	'	'	'	'
Litigation Settlement, Expense	'	$150,000	'	'	'	'	'	'	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2014
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Registration Of Securities, Value	$50
Issuance Of Securities, Post Effective Registration Statement, Value	$50